David Pham, MD
Pulmonary Disease · Westminster, CANPI 1043401698
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $472,338 of the $571,492 with a category attached, or 82.6%. AstraZeneca accounts for 71.7% of it on its own, with 31 other manufacturers making up the rest. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,126 payments — averaging $507.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$410K
- Sunovion Pharmaceuticals Inc.$98K
- GSK$23K
- Teva Pharmaceuticals USA, Inc.$12K
- Regeneron Healthcare Solutions, Inc.$9K
- Sanofi$6K
- plus $14K from 26 others
Across 509 payments — averaging $10,519 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.4M
- Sanofi US Services Inc.$1.4M
- Astrazeneca UK Limited$604K
- Novartis$433K
- Eli Lilly$381K
- Genentech, Inc.$188K
- plus $955K from 12 others
What the payments were for
- Consulting fees$19,0583%
- Speaking & faculty fees$472,33883%
- Travel & lodging$49,8129%
- Food & beverage$29,9705%
- Education$2970%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 568 | $409,572 |
| Sunovion Pharmaceuticals Inc. | 145 | $98,380 |
| GSK | 96 | $23,175 |
| Teva Pharmaceuticals USA, Inc. | 20 | $12,025 |
| Regeneron Healthcare Solutions, Inc. | 40 | $8,670 |
| Sanofi | 80 | $5,703 |
| Genentech USA, Inc. | 11 | $3,358 |
| Astrazeneca UK Limited | 23 | $3,067 |
| Novartis | 31 | $2,851 |
| Mylan Specialty L.p. | 20 | $1,359 |
| Boehringer Ingelheim | 27 | $660 |
| Sanofi-aventis U.S. LLC | 4 | $378 |
| Regeneron | 5 | $322 |
| Actelion Pharmaceuticals US, Inc. | 12 | $294 |
| Grifols Shared Services North America, Inc. | 2 | $289 |
| Genentech, Inc. | 4 | $248 |
| Insmed, Inc. | 7 | $202 |
| Aimmune Therapeutics, Inc. | 6 | $146 |
| Philips North America LLC | 5 | $114 |
| Verona Pharma, Inc. | 1 | $102 |
| Lundbeck LLC | 1 | $87 |
| Stryker | 2 | $85 |
| Nestle Healthcare Nutrition Inc. | 3 | $74 |
| Scilex Pharmaceuticals Inc. | 1 | $65 |
| Amgen | 2 | $64 |
| Optinose US, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Circassia Inc. | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Conmed Corporation | 1 | $29 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Electromed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$298,126
- AIRSUPRA$96,230
- LONHALA MAGNAIR$96,167
- NUCALA$18,533
- ArmonAir Digihaler$11,911
- ProAir Digihaler$11,911
- AirDuo RespiClick$11,911
- DUPIXENT$10,991
- XOLAIR$2,951
- TRELEGY ELLIPTA$1,950
- FASENRA$1,374
- Yupelri$905
- QBW251$792
- LATUDA$380
- BLENREP$125
- OFEV$120
- ANORO$118
- TEZSPIRE$114
- UPTRAVI$103
- OPSUMIT$103
How this compares
$571,492 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 646 | $630,227 |
| Dupixent SyringeDupilumab | 95 | $359,505 |
| UptraviSelexipag | 12 | $279,083 |
| TracleerBosentan | 15 | $181,918 |
| AdempasRiociguat | 12 | $168,927 |
| ZenpepLipase/Protease/Amylase | 28 | $109,486 |
| FasenraBenralizumab | 17 | $99,757 |
| Dupixent PenDupilumab | 26 | $95,884 |
| RestasisCyclosporine | 58 | $77,023 |
| XolairOmalizumab | 22 | $59,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $32,997 |
| Ventolin HfaAlbuterol Sulfate | 207 | $19,571 |
| VascepaIcosapent Ethyl | 19 | $18,223 |
| FarxigaDapagliflozin Propanediol | 24 | $17,684 |
| JanuviaSitagliptin Phosphate | 14 | $15,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Fasenra, Farxiga, Airsupra | $409,572 | $759,467699 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Tracleer | $294 | $461,00127 claims |
| Aimmune Therapeutics, Inc.Zenpep | $146 | $109,48628 claims |
| Genentech, Inc.Xolair | $248 | $59,94522 claims |
| GSKTrelegy Ellipta | $23,175 | $32,99723 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $65 | $1,06814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Westminster
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.